JP2019532970A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532970A5 JP2019532970A5 JP2019521706A JP2019521706A JP2019532970A5 JP 2019532970 A5 JP2019532970 A5 JP 2019532970A5 JP 2019521706 A JP2019521706 A JP 2019521706A JP 2019521706 A JP2019521706 A JP 2019521706A JP 2019532970 A5 JP2019532970 A5 JP 2019532970A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- complementarity determining
- dose
- chain complementarity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022173528A JP7562074B2 (ja) | 2016-10-24 | 2022-10-28 | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン |
| JP2024153940A JP2024170569A (ja) | 2016-10-24 | 2024-09-06 | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411783P | 2016-10-24 | 2016-10-24 | |
| US62/411,783 | 2016-10-24 | ||
| PCT/IB2017/001427 WO2018078442A2 (en) | 2016-10-24 | 2017-10-24 | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173528A Division JP7562074B2 (ja) | 2016-10-24 | 2022-10-28 | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019532970A JP2019532970A (ja) | 2019-11-14 |
| JP2019532970A5 true JP2019532970A5 (enExample) | 2020-12-03 |
Family
ID=60957345
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521706A Withdrawn JP2019532970A (ja) | 2016-10-24 | 2017-10-24 | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン |
| JP2022173528A Active JP7562074B2 (ja) | 2016-10-24 | 2022-10-28 | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン |
| JP2024153940A Pending JP2024170569A (ja) | 2016-10-24 | 2024-09-06 | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173528A Active JP7562074B2 (ja) | 2016-10-24 | 2022-10-28 | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン |
| JP2024153940A Pending JP2024170569A (ja) | 2016-10-24 | 2024-09-06 | インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3528845A2 (enExample) |
| JP (3) | JP2019532970A (enExample) |
| KR (2) | KR20190071785A (enExample) |
| CN (1) | CN110167593A (enExample) |
| AU (2) | AU2017352033A1 (enExample) |
| BR (1) | BR112019008156A2 (enExample) |
| CA (2) | CA3041434A1 (enExample) |
| EA (1) | EA201990930A1 (enExample) |
| IL (1) | IL266174B2 (enExample) |
| MX (2) | MX2019004766A (enExample) |
| SG (1) | SG11201903659WA (enExample) |
| WO (1) | WO2018078442A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
| SG10202108996PA (en) | 2015-05-07 | 2021-09-29 | Swedish Orphan Biovitrum Ag | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers |
| CN118165113B (zh) * | 2016-04-26 | 2025-10-28 | 恺兴生命科技(上海)有限公司 | 一种改善免疫应答细胞功能的方法 |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| WO2021185832A1 (en) | 2020-03-16 | 2021-09-23 | Swedish Orphan Biovitrum Ag | New therapeutic treatment |
| US20230149465A1 (en) * | 2020-04-06 | 2023-05-18 | Celledit Llc | Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling |
| WO2024254401A1 (en) | 2023-06-09 | 2024-12-12 | Children's Hospital Medical Center | Treatment of stem cell graft failure |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| EP1135415B1 (en) * | 1998-12-01 | 2010-08-11 | Facet Biotech Corporation | Humanized antibodies to gamma-interferon |
| ES2392073T3 (es) * | 2001-11-08 | 2012-12-04 | Abbott Biotherapeutics Corp. | Formulación farmacéutica líquida estable de anticuerpos IGG |
| UA92337C2 (uk) * | 2005-01-27 | 2010-10-25 | Новиммюн С.А. | ВИДІЛЕНЕ ПОВНІСТЮ ЛЮДСЬКЕ МОНОКЛОНАЛЬНЕ АНТИТІЛО ДО ГАММА-ІНТЕРФЕРОНУ (IFNγ), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ПОЛЕГШЕННЯ ІНТЕНСИВНОСТІ СИМПТОМУ АВТОІМУННОГО ЗАХВОРЮВАННЯ АБО ЗАПАЛЬНОГО РОЗЛАДУ |
| EP1888637A2 (en) * | 2005-05-19 | 2008-02-20 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| ES2511844T3 (es) | 2007-12-21 | 2014-10-23 | F. Hoffmann-La Roche Ag | Formulación de anticuerpo |
| EP2791168A1 (en) * | 2011-11-23 | 2014-10-22 | Amgen Inc. | Methods of treatment using an antibody against interferon gamma |
| KR20170018810A (ko) | 2014-06-10 | 2017-02-20 | 메이지 세이카 파루마 가부시키가이샤 | 안정한 아달리무맙 수성 제제 |
| SG10202108996PA (en) * | 2015-05-07 | 2021-09-29 | Swedish Orphan Biovitrum Ag | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers |
-
2017
- 2017-10-24 JP JP2019521706A patent/JP2019532970A/ja not_active Withdrawn
- 2017-10-24 EA EA201990930A patent/EA201990930A1/ru unknown
- 2017-10-24 BR BR112019008156-9A patent/BR112019008156A2/pt unknown
- 2017-10-24 CA CA3041434A patent/CA3041434A1/en active Pending
- 2017-10-24 IL IL266174A patent/IL266174B2/en unknown
- 2017-10-24 KR KR1020197014837A patent/KR20190071785A/ko not_active Ceased
- 2017-10-24 EP EP17829009.4A patent/EP3528845A2/en active Pending
- 2017-10-24 SG SG11201903659WA patent/SG11201903659WA/en unknown
- 2017-10-24 CN CN201780080221.6A patent/CN110167593A/zh active Pending
- 2017-10-24 CA CA3244670A patent/CA3244670A1/en active Pending
- 2017-10-24 WO PCT/IB2017/001427 patent/WO2018078442A2/en not_active Ceased
- 2017-10-24 AU AU2017352033A patent/AU2017352033A1/en not_active Abandoned
- 2017-10-24 KR KR1020247033365A patent/KR20240148970A/ko not_active Ceased
- 2017-10-24 MX MX2019004766A patent/MX2019004766A/es unknown
-
2019
- 2019-04-24 MX MX2025012950A patent/MX2025012950A/es unknown
-
2022
- 2022-10-28 JP JP2022173528A patent/JP7562074B2/ja active Active
-
2024
- 2024-09-06 JP JP2024153940A patent/JP2024170569A/ja active Pending
- 2024-11-12 AU AU2024264563A patent/AU2024264563A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114286828A (zh) | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 | |
| IL317348A (en) | Stable formulations of PROGRAMMED DEATH RECEPTOR 1 (PD–1) antibodies and methods of using them | |
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| KR102104296B1 (ko) | 종양성 질병들에 대한 치료 | |
| JP2018515493A5 (enExample) | ||
| JP2014114288A5 (enExample) | ||
| US20250025583A1 (en) | Method of treatment of neuroendocrine tumors | |
| AU2015313827C1 (en) | Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients | |
| JP2020502219A5 (enExample) | ||
| JP2025515092A5 (enExample) | ||
| JP2019519584A5 (enExample) | ||
| JP2026001086A (ja) | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 | |
| WO2025002280A1 (en) | Combination therapies for the treatment of cancer | |
| BR112020008375A2 (pt) | métodos de reduzir efeitos colaterais de terapia conjugada com fármacos de anticorpo anti-cd30 | |
| CN115957321A (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| TW202319073A (zh) | 用於治療肺癌的組合療法 | |
| JP2024521105A5 (enExample) | ||
| JP2024519449A (ja) | がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用 | |
| CN116113411A (zh) | 用于治疗软组织肉瘤的联用药物 | |
| JP2022530599A5 (enExample) | ||
| TW202034925A (zh) | Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途 | |
| JP2025526402A5 (enExample) | ||
| KR20230167968A (ko) | 점도 감소 부형제 조성물 및 이를 포함하는 저점도 고농축 단백질 제형 | |
| JP2016527200A (ja) | Ｃｄ３７抗体とクロラムブシルの併用 | |
| US20250019441A1 (en) | Treatment of cancer with anti-ilt2 antibodies |